LEXX Lexaria Bioscience Corp.
Healthcare$0.67+2.37%ClosedMarket Cap: $13.6M
As of 2026-05-26
Valuation
P/E (TTM)
—
PEG
—
P/B
2.41
P/S
36.11
EV/EBITDA
-0.88
DCF Value
$-1.83
FCF Yield
-71.0%
Div Yield
0.0%
Margins & Returns
Gross Margin
100.0%
Operating Margin
-2571.9%
Net Margin
-2589.7%
ROE
-190.1%
ROA
-146.9%
ROIC
-150.1%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q2 null | $20.0K | 100.0% | $-1.5M | $-1.4M | $— | — |
| Q1 null | $0.00 | NaN% | $-1.6M | $-1.6M | $— | — |
| Q4 null | $174.0K | 100.0% | $-2.7M | $-2.7M | $— | — |
| FY null | $705.9K | 99.6% | $-11.9M | $-11.9M | $— | — |
| Q3 null | $174.0K | 100.0% | $-3.8M | $-3.8M | $— | — |
| Q2 null | $174.0K | 100.0% | $-2.8M | $-2.7M | $— | — |
| Q1 null | $183.9K | 98.5% | $-2.7M | $-2.7M | $— | — |
| Q4 null | $84.0K | 100.0% | $-2.2M | $-2.2M | $— | — |
| FY null | $464.3K | 99.0% | $-5.8M | $-5.8M | $— | — |
| Q3 null | $84.0K | 100.0% | $-1.7M | $-1.8M | $— | — |
| Q2 2024 | $145.0K | 89.0% | $-668.0K | $-649.5K | $-0.06 | — |
| Q1 2024 | $151.3K | 70.6% | $-1.1M | $-1.2M | $-0.13 | — |